PubRank

Margaretha Rudas

Author PubWeight™ 48.76‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011 2.79
2 Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol 2007 1.90
3 Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J Clin Invest 2011 1.88
4 Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 2004 1.72
5 Intensified local treatment and systemic therapy significantly increase survival in patients with brain metastases from advanced breast cancer - a retrospective analysis. Radiother Oncol 2006 1.63
6 Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer. Int J Cancer 2003 1.50
7 Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer. Wien Klin Wochenschr 2004 1.45
8 Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007 1.42
9 Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Arch 2012 1.37
10 CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res 2012 1.33
11 Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2012 1.32
12 US-guided 14-gauge core-needle breast biopsy: results of a validation study in 1352 cases. Radiology 2008 1.20
13 Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. Virchows Arch 2002 1.12
14 Axillary lymph node metastases in patients with breast carcinomas: assessment with nonenhanced versus uspio-enhanced MR imaging. Radiology 2006 1.09
15 Do we need HER-2/neu testing for all patients with primary breast carcinoma? Cancer 2003 1.05
16 Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches. Clin Neuropathol 2012 1.05
17 The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res 2014 1.04
18 Preoperative core needle biopsy does not increase local recurrence rate in breast cancer patients. Breast Cancer Res Treat 2006 1.03
19 MRI-only lesions: application of diffusion-weighted imaging obviates unnecessary MR-guided breast biopsies. Eur Radiol 2014 1.02
20 Orthotopic microvascular reanastomosis of whole cryopreserved ovine ovaries resulting in pregnancy and live birth. Fertil Steril 2006 1.01
21 Stereotactic 11-gauge vacuum-assisted breast biopsy: a validation study. AJR Am J Roentgenol 2002 1.01
22 Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14. J Clin Oncol 2007 1.00
23 Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2005 0.98
24 High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin. J Clin Oncol 2003 0.97
25 Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy. Breast Cancer Res Treat 2003 0.93
26 Image quality, lesion detection, and diagnostic efficacy in digital mammography: full-field digital mammography versus computed radiography-based mammography using digital storage phosphor plates. Eur J Radiol 2007 0.92
27 Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer. Breast Cancer Res Treat 2003 0.88
28 Neoadjuvant chemotherapy increases the rate of breast conservation in lobular-type breast cancer patients. Ann Surg Oncol 2011 0.88
29 Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy. Clin Cancer Res 2009 0.87
30 Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. Eur J Cancer 2012 0.87
31 Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer. BMC Cancer 2009 0.86
32 Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer. Breast Cancer Res Treat 2006 0.86
33 Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment. Clin Cancer Res 2007 0.84
34 Gene expression of PMP22 is an independent prognostic factor for disease-free and overall survival in breast cancer patients. BMC Cancer 2010 0.84
35 Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer. Cancer Chemother Pharmacol 2008 0.83
36 CDK10 is not a target for aberrant DNA methylation in breast cancer. Anticancer Res 2009 0.82
37 Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer. Clin Cancer Res 2011 0.82
38 Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer. Breast J 2013 0.81
39 Breast-conserving surgery for T3/T4 breast cancer: an analysis of 196 patients. Breast Cancer Res Treat 2007 0.80
40 The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer. Breast Cancer Res Treat 2008 0.79
41 [Stereotactically and sonographically guided vacuum-assisted breast biopsy: a national consensus for Austria]. Rofo 2002 0.78
42 TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family. Breast Cancer Res Treat 2015 0.78
43 Diagnostic accuracy of (18)F-FDG PET/CT compared with that of contrast-enhanced MRI of the breast at 3 T. Eur J Nucl Med Mol Imaging 2015 0.78
44 Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients. Pharmacoeconomics 2015 0.78
45 The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status. J Cancer Res Clin Oncol 2005 0.77
46 BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy. Cancer Chemother Pharmacol 2014 0.77
47 Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy. Anticancer Drugs 2015 0.75
48 Factors influencing the time to development of brain metastases in breast cancer. Breast 2008 0.75
49 Can galactography-guided stereotactic, 11-gauge, vacuum-assisted breast biopsy of intraductal lesions serve as an alternative to surgical biopsy? Eur Radiol 2009 0.75